blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2381254

EP2381254 - Copolymer assay [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  16.06.2017
Database last updated on 24.08.2024
Most recent event   Tooltip16.06.2017Patent maintained (B2 publication)published on 19.07.2017  [2017/29]
Applicant(s)For all designated states
Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge, MA 02142 / US
[2017/29]
Former [2011/43]For all designated states
Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge, MA 02142 / US
Inventor(s)01 / D'Alessandro, Josephine S.
16 Seaview Avenue
Marblehead, MA 01945 / US
02 / Kishimoto, Takashi Kei
46 Coolidge Avenue
Lexington, MA 02420 / US
03 / Healy, Aileen
33 Coolidge Road
Medford, MA 02155 / US
 [2013/51]
Former [2011/43]01 / D'Alessandro, Josephine S.
16 Seaview Avenue
Marblehead, MA Massachusetts 01945 / US
02 / Kishimoto, Takashi Kei
46 Coolidge Avenue
Lexington, MA Massachusetts 02420 / US
03 / Healy, Aileen
33 Coolidge Road
Medford, MA Massachusetts 02155 / US
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2017/29]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2011/43]Coehn, Markus
Fish & Richardson P.C. Mies-van-der-Rohe-Strasse 8
80807 München / DE
Application number, filing date11172109.819.06.2008
[2011/43]
Priority number, dateUS20070945488P21.06.2007         Original published format: US 945488 P
[2011/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2381254
Date:26.10.2011
Language:EN
[2011/43]
Type: B1 Patent specification 
No.:EP2381254
Date:16.04.2014
Language:EN
[2014/16]
Type: B2 New European patent specification 
No.:EP2381254
Date:19.07.2017
Language:EN
[2017/29]
Search report(s)(Supplementary) European search report - dispatched on:EP26.09.2011
ClassificationIPC:G01N33/50, C07K14/00
[2011/43]
CPC:
C07K14/001 (EP,US); A61P1/04 (EP); A61P19/02 (EP);
A61P25/00 (EP); A61P29/00 (EP); G01N33/5008 (EP,US);
G01N2333/52 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/43]
Extension statesALNot yet paid
BANot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:Copolymeranalyse[2011/43]
English:Copolymer assay[2011/43]
French:Analyse de copolymères[2011/43]
Examination procedure30.06.2011Examination requested  [2011/43]
04.11.2011Despatch of a communication from the examining division (Time limit: M06)
20.06.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
03.08.2012Reply to a communication from the examining division
06.09.2012Despatch of a communication from the examining division (Time limit: M04)
12.12.2012Reply to a communication from the examining division
20.11.2013Communication of intention to grant the patent
10.03.2014Fee for grant paid
10.03.2014Fee for publishing/printing paid
Parent application(s)   TooltipEP08780866.3  / EP2174130
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080780866) is  26.10.2010
Opposition(s)Opponent(s)01  15.01.2015  23.02.2015  ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  15.01.2015  01.09.2016  WITHDRAWN
Actavis Group PTC EHF
Reykjavikurvegi 76-78
220 Hafnarfjordur / IS
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 [2016/41]
Former [2015/08]
Opponent(s)01  15.01.2015    ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 02  15.01.2015    WITHDRAWN
Actavis Group PTC EHF
Reykjavikurvegi 76-78
220 Hafnarfjordur / IS
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
26.02.2015Invitation to proprietor to file observations on the notice of opposition
06.11.2015Reply of patent proprietor to notice(s) of opposition
25.11.2016Legal effect of interlocutory decision in opposition
25.11.2016Date of oral proceedings
09.12.2016Despatch of interlocutory decision in opposition
09.12.2016Despatch of minutes of oral proceedings
29.03.2017Despatch of communication that the patent will be maintained as amended
09.06.2017Fee for printing new specification paid
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
03.08.2012Request for further processing filed
03.08.2012Full payment received (date of receipt of payment)
Request granted
13.08.2012Decision despatched
Fees paidRenewal fee
30.06.2011Renewal fee patent year 03
30.06.2011Renewal fee patent year 04
31.03.2012Renewal fee patent year 05
27.06.2013Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.06.2008
AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
MT16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
TR16.04.2014
IE19.06.2014
LU19.06.2014
CH30.06.2014
LI30.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
[2016/33]
Former [2016/32]HU19.06.2008
AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
MT16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
IE19.06.2014
LU19.06.2014
CH30.06.2014
LI30.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2016/16]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
MT16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
IE19.06.2014
LU19.06.2014
CH30.06.2014
LI30.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/36]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SI16.04.2014
SK16.04.2014
IE19.06.2014
LU19.06.2014
CH30.06.2014
LI30.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/21]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
IE19.06.2014
LU19.06.2014
CH30.06.2014
LI30.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/20]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
LU19.06.2014
CH30.06.2014
LI30.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/18]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
IT16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
LU19.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/11]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
RO16.04.2014
SE16.04.2014
SK16.04.2014
LU19.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/10]AT16.04.2014
BE16.04.2014
CY16.04.2014
CZ16.04.2014
DK16.04.2014
EE16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
SE16.04.2014
SK16.04.2014
LU19.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/09]AT16.04.2014
BE16.04.2014
CY16.04.2014
DK16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
MC16.04.2014
PL16.04.2014
SE16.04.2014
LU19.06.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/08]AT16.04.2014
BE16.04.2014
CY16.04.2014
DK16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2015/02]AT16.04.2014
CY16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
PT18.08.2014
Former [2014/51]AT16.04.2014
CY16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
Former [2014/50]CY16.04.2014
FI16.04.2014
HR16.04.2014
LT16.04.2014
LV16.04.2014
PL16.04.2014
SE16.04.2014
BG16.07.2014
NO16.07.2014
GR17.07.2014
IS16.08.2014
Former [2014/49]CY16.04.2014
FI16.04.2014
LT16.04.2014
BG16.07.2014
NO16.07.2014
IS16.08.2014
Former [2014/48]CY16.04.2014
LT16.04.2014
BG16.07.2014
Former [2014/47]CY16.04.2014
Documents cited:Search[Y]WO03048735  (TEVA PHARMA [IL], et al) [Y] 1-15 * claims 3,8,16-17 *;
 [XY]  - LI ET AL, "Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma.", EUROPEAN JOURNAL OF PHARMACOLOGY, (19980101), vol. 342, no. 2-3, ISSN 0014-2999, pages 303 - 310, XP055006978 [X] 1,3,7,15 * abstract; section 2; Figs. 1-3; Table 1, footnote b; Fig. 3, caption * [Y] 2,4-6,8-14

DOI:   http://dx.doi.org/10.1016/S0014-2999(97)01509-4
 [Y]  - LI Q Q ET AL, "Glatiramer acetate inhibition of tumor necrosis factor-alpha-induced RANTES expression and release from U-251 MG human astrocytic cells.", JOURNAL OF NEUROCHEMISTRY JUN 2001, (200106), vol. 77, no. 5, ISSN 0022-3042, pages 1208 - 1217, XP002494417 [Y] 1-15 * figures 1-4 *

DOI:   http://dx.doi.org/10.1046/j.1471-4159.2001.00327.x
 [Y]  - MILO R ET AL, Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein., JOURNAL OF NEUROIMMUNOLOGY SEP 1995, VOL. 61, NR. 2, PAGE(S) 185 - 193, (199509), ISSN 0165-5728, XP002494420 [Y] 1-15 * page 189 * * abstract *

DOI:   http://dx.doi.org/10.1016/0165-5728(95)00085-G
 [Y]  - FARINA C ET AL, "Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.", BRAIN : A JOURNAL OF NEUROLOGY APR 2001, (200104), vol. 124, no. Pt 4, ISSN 0006-8950, pages 705 - 719, XP002494418 [Y] 1-15 * pages 708-709 * * abstract *

DOI:   http://dx.doi.org/10.1093/brain/124.4.705
 [Y]  - BEN ABDELAZIZ HALIM ET AL, "Inhibition of TNF-alpha production in THP-1 macrophages by glatiramer acetate does not alter their susceptibility to infection by Listeria monocytogenes and does not impair the efficacy of ampicillin or moxifloxacin against intracellular bacteria", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (200407), vol. 54, no. 1, ISSN 0305-7453, pages 288 - 289, XP002494419 [Y] 1-15 * page 288 *

DOI:   http://dx.doi.org/10.1093/jac/dkh288
by applicantUS4683202
 US6251639
 US6692918
    - KLEIN ET AL., J1MMUUø, (2004), vol. 172, pages 550 - 559
    - Methods In Enzymology, vol. 154, 155
    - Weir 's Handbook OfExperimental Immunology, (1996), vol. I-IV
    - Current Protocols in Molecular Biology, JOHN WILEY & SONS, INC., (1994), vol. 1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.